Ethyl 6,8-dichlorocaprylate pharma grade is supplied as an active pharmaceutical ingredient for solid oral and injectable finished dosage forms, specifically tablet, capsule, granule, injection, oral liquid, and injectable application. The product is assigned model designation EDC-C8-PG-240 for oral solid processing and EDC-C8-PG-INJ for parenteral manufacturing; both grades are derived from the same synthetic route but differ in bioburden, endotoxin, and particulate controls. The compound is chemically described as ethyl 6,8-dichlorooctanoate, with a calculated molecular weight of 241.15 g/mol and halogen mass fraction of 29.4% chlorine by weight. It is produced as a white to off-white crystalline powder and is packaged in double low-density polyethylene bags inside a fibre drum with nitrogen overlay. The API is not an excipient and is not interchangeable with technical-grade chlorinated octanoate esters used in non-pharmaceutical synthesis; residual solvent and elemental impurity controls follow ICH Q3C(R8) and ICH Q3D. Storage at 15–25°C in a dry environment is specified because the ester linkage and terminal chlorines can hydrolyze under alkaline conditions. This document provides the specification basis, processing constraints, injectable requirements, and differences from structurally adjacent esters used in oral and parenteral formulation development.

For granule, tablet, and capsule manufacturing, the oral solid grade is milled to a particle size distribution with D90 ≤74 µm and D50 10–25 µm by laser diffraction under USP <429>. The injectable grade is not processed through the same non-sterile jet mill; it is micronized under controlled air and supplied with reduced bioburden. The tablet and capsule grade may be granulated by dry or wet processes, whereas the injection grade is intended for dissolution in non-aqueous vehicles, not for aqueous lyophilization unless solubility and stability have been demonstrated. Aqueous solubility of the non-ionized ester is expected to be low, likely below 100 µg/mL at 25°C; published intrinsic solubility data for this exact derivative are limited and should be confirmed by shake-flask method under USP <1236> or equivalent. Because the molecule contains no basic or acidic ionisable center that dominates solid-state handling, solubility enhancement in parenteral vehicles depends on lipophilic cosolvents or oils rather than pH adjustment.

Specifications governing identity, purity, and residual solvent limits

The pharmacopoeial-type specification below aligns with USP <467>, USP <429>, USP <921>, USP <232>/<233>, USP <61>/<62>, USP <790>, and ICH Q3C(R8) where applicable. Acceptance limits are set for multi-dose oral and parenteral processing; the parenteral grade uses the tighter water and endotoxin limits shown.

Residual solvent control is not optional for pharma-grade designation. Technical-grade lots obtained without solvent exchange frequently retain ethyl acetate or dichloromethane above ICH Q3C(R8) limits and are unsuitable for tablet, capsule, or injection. The API is recrystallized from ethanol-water mixtures, dried under vacuum at 40–50°C, and milled under nitrogen. Each batch is tested by headspace GC using USP <467> procedure A; acceptance values are assigned according to the maximum daily dose. For an expected oral dose of 250 mg/day, a dichloromethane limit of 600 ppm yields daily exposure below the 6.0 mg/day concentration limit defined in ICH Q3C(R8).

Particle size distribution is controlled because direct compression at 60,000 tablets/h on a rotary press with 10 mm round tooling requires D90 not exceeding 74 µm to maintain content uniformity below 5.0% relative standard deviation across 20 sampling points. The micronization step should be followed by equilibrated storage for 24 h at 20–25°C and 40–50% relative humidity to dissipate triboelectric charge before sieving. This practice is consistent with USP <1174> powder flow characterization and avoids electrostatic adhesion in lubricated blends.

What process controls are required for tablet and capsule dosage forms?

No public production-scale data for the 6,8-dichloro compound were located; the processing ranges below reflect standard practice for fine lipophilic esters with similar particle size and require pilot-scale confirmation. For tablet formulations relying on direct compression, the API is first screened through a 500 µm sieve and blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and colloidal silicon dioxide in a V-blender or bin blender at 25 rpm for 15 min. Magnesium stearate is added in the final 3 min at 0.5–1.0% w/w. Compression is performed at 8–12 kN using 10 mm round or caplet tooling; punch sticking should be monitored because fine particulate lipophilic APIs can adhere to tool steel when lubricant levels are inadequate or when moisture exceeds 3.0%.

Wet granulation is used when API content exceeds 30% by weight or when compressibility is poor. In a high-shear granulator, the dry mix is blended for 3 min at impeller 200 rpm and chopper 1500 rpm, then granulated with purified water or ethanol-water 70:30 to a target loss on drying of 2.0–4.0%. Drying in a fluid bed is conducted at inlet air 50–60°C until final loss on drying is 1.5–2.5%. Drying above 65°C is avoided to limit ester hydrolysis and crystalline surface disorder. Milling through a 0.8 mm screen using a cone mill at 1500 rpm is acceptable for size reduction, but milling in the presence of water or under humid air should be avoided.

For capsule filling, low-dose formulations are prepared by geometric dilution with lactose monohydrate before final blending. Content uniformity issues at scale are commonly related to particle size segregation; this is addressed by adding 1.0% w/w colloidal silicon dioxide and mixing for 15 min at 25 rpm. The final blend is passed through an 850 µm screen before encapsulation. A tamping-pin capsule filler operating at 70,000 capsules/h usually requires a Carr index below 25% and moisture below 3.0% to avoid bridging and weight variation. Immediate-release tablets are tested under USP <711> Apparatus 2 at 50 rpm in 900 mL of dissolution medium; where sink conditions require surfactant, the level is justified according to USP <1092> rather than added arbitrarily.

Granule dosage forms may be prepared by extrusion-spheronization using microcrystalline cellulose and lactose with water as binder, then dried in a fluid bed at 60°C inlet until loss on drying is 1.5–2.5%. The API should be added in the dry blend rather than the binder solution to minimize hydrolytic degradation during wet massing. Excipients with reactive primary amine groups, such as meglumine or amino sugar excipients, should be avoided above 50°C during drying because terminal alkyl chloride displacement may occur.

When the injectable route requires low endotoxin and particulate burden

When the injectable route requires low endotoxin and particulate burden, the parenteral grade is dissolved in a water-free vehicle because the API has poor aqueous solubility. Suitable vehicles include sesame oil, medium-chain triglycerides, or a non-aqueous cosolvent system such as polyethylene glycol 300 and ethanol. The solution is pre-filtered through a 0.45 µm membrane and then through a sterile 0.22 µm polyvinylidene fluoride filter; warming to 30–35°C may be necessary to reduce vehicle viscosity and increase filtration flux. Nylon filters may adsorb lipophilic esters and should be avoided unless filter compatibility is demonstrated under USP <1664> or equivalent.

Bacterial endotoxin limits for the API are set at ≤0.25 EU/mg for parenteral grade, but the finished product endotoxin limit must be derived from the maximum dose per kilogram and the route of administration. Particulate matter in the finished injection must meet compendial limits under USP <787> or USP <788>; visible particles and subvisible particle counts are determined after sterile filtration. The API itself is not supplied sterile; terminal sterilization of the finished injectable by moist heat at 121°C for 15 min is not established for this compound. Published data for hydrolytic degradation of the dichloro ester under moist-heat sterilization are limited, and stability studies should be generated according to ICH Q1A(R2) before adopting terminal sterilization. Steam sterilization may accelerate ester hydrolysis in non-aqueous vehicles containing trace water; sterile filtration remains the preferred process route unless the vehicle and primary packaging are demonstrated to withstand thermal cycling.

Aqueous dilution can cause precipitation of the non-ionized API. Parenteral formulations should therefore not be diluted with water, sodium chloride injection, or dextrose injection unless a validated cosolvent system is present and precipitation studies confirm stability for the intended infusion period. In-use stability for opened ampoules or vials should be evaluated at 20–25°C and protected from light for at least the maximum administration time; published data for this specific configuration are limited, and the period should be confirmed by subvisible particulate testing and assay during formulation development.

Why the 6,8-dichloro substitution pattern alters handling and compatibility relative to non-halogenated octanoate esters

The 6,8-dichloro substitution distinguishes this API from ethyl caprylate NF and from alkyl-bromide intermediates used in synthesis. The two chlorine atoms contribute 70.90 g/mol to the calculated 241.15 g/mol molecular weight and produce a chlorine mass fraction of 29.4%. In comparison, ethyl caprylate has a calculated molecular weight of 172.27 g/mol and contains no halogen. This substitution is expected to reduce vapor pressure and increase partition into lipophilic vehicles relative to non-halogenated octanoate esters, but experimental log P and pKa data for this specific configuration are not consistently published and should not be extrapolated from caprylate ester data without stress-study verification. In silico fragment estimates place the octanol-water partition coefficient in the approximate range 3.5–4.0, but no experimental log P is cited in the product technical file.

The manufacturing route for the pharma grade is therefore not equivalent to the base-catalyzed esterification used for unsubstituted caprylate esters. Residual inorganic chloride and organochlorine impurities are quantified by ion chromatography and USP <233>; technical-grade esters may not meet the same limits. In oral formulations, the chlorinated termini can react with primary or secondary amine excipients or amine-functional drug substances under elevated granulation drying. This incompatibility is not observed with unsubstituted ethyl caprylate and must be addressed by avoiding amine-based additives or by reducing drying temperature below 60°C. Compared with the brominated analogue, the chloro derivative offers lower halogen mass and generally lower reactivity toward nucleophilic substitution; however, direct substitution into an existing formulation is not permitted without impurity profiling because residual organobromine compounds and their degradation products differ substantially from chlorinated analogues.

For packaging in aluminium foil pouches under nitrogen, the retest interval is set at 24 months when stored at 15–25°C and protected from moisture. Long-term stability lots are loaded into ICH Q1A(R2) conditions of 25°C/60% RH for solid oral grade and 5°C for injectable grade; accelerated conditions of 40°C/75% RH are applied only for solid oral grade because the parenteral vehicle may phase-separate or oxidize. The API is labile to alkaline hydrolysis and should not be milled in the presence of water. Avoid contact with strong bases, primary amines, sodium borohydride, and catalytic hydrogenation until compatibility is confirmed. Bags should be resealed under dry nitrogen after each use; bulk containers exposed to ambient air for more than 4 h at 60% RH should be re-tested for water content before release for tableting or capsule filling.